Articles published by DIAGONAL THERAPEUTICS, INC

Diagonal’s First-in-Class Clustering Antibody, DIAG723, Receives Orphan Drug Designation (ODD) from U.S. FDA and an ODD Positive Opinion from EMA for Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

June 18, 2025

From DIAGONAL THERAPEUTICS, INC

Via GlobeNewswire

Diagonal Therapeutics to Present New Preclinical Data Demonstrating Disease-Modifying Potential of Receptor Clustering Antibody Approach in HHT at EHA 2025 Congress

June 12, 2025

From DIAGONAL THERAPEUTICS, INC

Via GlobeNewswire

Diagonal Therapeutics Initiates Natural History Study of Adults Living with Hereditary Hemorrhagic Telangiectasia (HHT), a Rare Bleeding Disorder with No Approved Treatments

March 04, 2025

From DIAGONAL THERAPEUTICS, INC

Via GlobeNewswire

Diagonal Therapeutics to Present Data at ASH 2024 Demonstrating the Economic and Clinical Burden of Hereditary Hemorrhagic Telangiectasia (HHT)

December 03, 2024

From DIAGONAL THERAPEUTICS, INC

Via GlobeNewswire

Diagonal Therapeutics to Present at the Cure HHT’s 15th International Scientific Conference

October 08, 2024

From DIAGONAL THERAPEUTICS, INC

Via GlobeNewswire

Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseases

April 03, 2024

From DIAGONAL THERAPEUTICS, INC

Via GlobeNewswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.